A RAS-inhibitor case study shows how teams can move from a high-profile clinical result and a patent dispute to compound-level competitive intelligence—without manually reviewing hundreds of structures.
THE RESEARCH QUESTION
How similar are the compounds behind two competing RAS programs—and where do the similarities end?
LCA finds the disclosed compounds that deserve attention. SAR explains which structural features may drive meaningful differences.
At ASCO 2026, Revolution Medicines’ daraxonrasib (RMC-6236) became one of the meeting’s most discussed oncology readouts. In previously treated metastatic pancreatic cancer, the investigational multi-selective RAS(ON) inhibitor delivered a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy, and reduced the risk of death by 40%. The presentation reportedly received a 42-second standing ovation.
MEDIAN OVERALL SURVIVAL
13.2 vs. 6.7 months
RISK OF DEATH
40% reduction
ASCO RESPONSE
42 seconds
That clinical milestone was only one part of a much larger competitive-intelligence story.
Erasca is developing ERAS-0015, another RAS molecular-glue program. Revolution Medicines has alleged that ERAS-0015 infringes patents covering its own work and has taken legal action against Erasca. The dispute turns an abstract question about “competitive overlap” into a concrete scientific and strategic question.
Answering that question requires more than reading a trial abstract, a press release or the front page of a patent. It requires researchers to locate the relevant chemical series, identify representative lead compounds, normalize biological assays, compare potency and selectivity, examine shared scaffolds and trace the structural modifications that may drive functional differences.
This is exactly where Lead Compound Analysis (LCA) and Structure–Activity Relationship (SAR) analysis can change the research workflow.
The intelligence gap between a headline and a molecule
Competitive events arrive as fragments: a clinical result, a newly published patent, a financing disclosure, a litigation filing or a rival program update. Each source answers a different question. None provides a ready-made view of the chemical competition.
- Identify the patents most closely associated with each program.
- Review large numbers of disclosed compounds and examples.
- Extract structures, activities, assay conditions and substituent changes.
- Determine which examples are plausible lead compounds.
- Compare series that may use different numbering, assay formats and reporting conventions.
- Separate meaningful similarity from superficial resemblance.
THE REAL BOTTLENECK
The bottleneck is not access to documents. It is turning scattered patent disclosures into a consistent, decision-ready evidence model.
One case, two patent families, one strategic question
| Patent | Company / applicant | Focus | Associated competitive space |
|---|---|---|---|
| WO2022060836 | Revolution Medicines | Indole derivatives as RAS inhibitors for cancer treatment | RMC-6236 / daraxonrasib-associated chemical space |
| WO2024067857 | Guangzhou Joyo Pharmatech | Macrocyclic derivatives and their uses | ERAS-0015-associated chemical space |
The goal is not to reach a legal conclusion. It is to build a transparent scientific comparison that helps R&D, business development, competitive intelligence and IP teams ask better questions.
LCA: finding the compounds that deserve attention
Patent specifications can contain hundreds or thousands of compounds. Treating every example as equally important makes analysis slow and often obscures the true centers of gravity in a series.
Lead Compound Analysis (LCA) is designed to screen disclosed compounds at scale and surface the candidates most likely to matter. It brings structure, biological activity, potency, selectivity and pharmacological evidence into one analytical workflow.
What LCA does in this case
- Map the disclosed chemical series. Identify compounds, example families and recurring structural motifs.
- Prioritize representative leads. Rank compounds using available activity and pharmacology evidence.
- Normalize the evidence. Organize endpoints, potency values and experimental context.
- Expose evidence gaps. Separate reported measurements from sparse or incomparable data.
- Create a defensible shortlist. Give experts a manageable set of compounds for deeper review.
The result is not simply a shorter patent summary. It is a compound-level map of where the strongest disclosed evidence sits.
SAR: explaining why structural differences matter
Once representative compounds have been identified, the next question is mechanistic: what structural features appear to be associated with changes in activity?
Structure–Activity Relationship (SAR) analysis connects chemical structure with biological performance. It can highlight shared scaffolds, substituent patterns, ring constraints, stereochemical features and other modifications across a compound series, then relate those changes to the available activity data.
What SAR helps the team investigate
- Which scaffold features recur across the disclosed macrocyclic series.
- Where substitutions or ring modifications create meaningful branches.
- Which changes coincide with stronger or weaker reported activity.
- Whether structural convergence is broad or concentrated in specific molecular regions.
- Which hypotheses deserve expert medicinal-chemistry review.
A similarity score says that two structures resemble each other. SAR helps explain which features are shared, which are different and whether those differences may be functionally meaningful.
LCA and SAR are stronger together
| Research question | LCA | SAR |
|---|---|---|
| Which compounds deserve attention? | Primary | Supporting |
| Where is the strongest disclosed activity evidence? | Primary | Supporting |
| What is the shared scaffold or structural pattern? | Supporting | Primary |
| Which modifications correlate with activity changes? | Supporting | Primary |
| How do competing patent series compare? | Lead prioritization | Structural interpretation |
THE CONNECTED WORKFLOW
Signal → patent set → compound extraction → lead prioritization → SAR interpretation → expert review → strategic action
LCA reduces the search space. SAR increases the explanatory power of the shortlist. Together, they allow a team to move from “these programs may overlap” to a more precise evidence package describing the relevant compounds, structural relationships, activity patterns and unresolved questions.
What changes for R&D and competitive-intelligence teams
1. Earlier insight from newly published patents
A new patent can be evaluated before the market has formed a consensus around the program. Teams can identify promising compounds and structural themes while the competitive signal is still fresh.
2. A shared evidence layer across functions
Medicinal chemistry, biology, IP, business development and competitive intelligence often examine the same program from different angles. A compound-level analysis gives those teams a common reference point without pretending that one model replaces specialist judgment.
3. Faster hypothesis generation
Instead of spending the first phase of a project locating and transcribing examples, scientists can begin with an organized shortlist and focus their time on interpretation, caveats and experimental hypotheses.
4. More traceable decision support
High-quality analysis should preserve the path back to the underlying patent examples and reported assays. This matters when a conclusion will influence portfolio choices, diligence priorities or an IP discussion.
5. A repeatable monitoring workflow
Competitive landscapes do not stand still. The same analytical pattern can be rerun when a continuation patent, new assay package, clinical update or competitor disclosure appears.
What AI should—and should not—decide
AI can accelerate compound extraction, organization, ranking and pattern discovery. It should not turn incomplete patent data into false certainty.
Keep the analytical boundaries explicit
- Cross-patent assay values may not be directly comparable.
- A disclosed example is not automatically a development candidate.
- Structural similarity alone does not establish equivalent pharmacology, clinical performance or patent infringement.
- Missing data is an analytical result, not permission to invent a value.
- Final scientific and legal conclusions require expert review.
The value of AI is therefore not autonomous judgment. It is the ability to make a large, fragmented evidence base tractable, traceable and ready for expert reasoning.
From patent publication to competitive action
The daraxonrasib–ERAS-0015 case illustrates a wider shift in life-sciences intelligence. A headline may tell the market that something important happened. LCA and SAR help explain what may be happening at the molecule level.
From a newly published patent to compound-level competitive intelligence—identify what matters, understand why it matters and see how competing chemical series compare.
Use Lead Compound Analysis when the first challenge is finding the strongest compounds in a large patent landscape. Use Structure–Activity Relationship analysis when the next challenge is interpreting the structural logic and activity patterns within or across those series. Use them together when the decision requires both prioritization and explanation.
Start with your own competitive question
Choose two patent families, a fast-moving target or a competitor program. Run LCA to surface the lead compounds and evidence. Then use SAR analysis to examine the structural features, modifications and activity relationships that define the competitive space.
Sources
- ASCO: Multi-selective RAS inhibitor nearly doubles survival in pancreatic cancer
- National Cancer Institute: ASCO 2026 reflections
- Erasca SEC filing dated April 27, 2026
This article is intended for scientific and competitive-intelligence discussion. It does not provide legal advice or make a conclusion regarding patent validity, infringement or freedom to operate.